Top

Published in:

01-01-2005 | Original Article

Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study

Authors: J. A. Kanis, F. Borgström, O. Johnell, A. Oden, D. Sykes, B. Jönsson

Published in: Osteoporosis International | Issue 1/2005

Abstract

Raloxifene treatment has been shown to reduce the risk of vertebral fractures and breast cancer in postmenopausal women. The long-term economic implications of treatment with raloxifene have not yet been investigated. The aim of this study was to assess the cost-effectiveness of treating postmenopausal women in the UK with raloxifene. A previously developed computer simulation model was used to estimate the cost-effectiveness of osteoporotic treatments with extra skeletal benefits. The model was populated with epidemiological data and cost data relevant for a UK female population. Data on the effect of treatment were taken from the Multiple Outcomes of Raloxifene (MORE) study, which recruited women with low bone mineral density or with a prior vertebral fracture. Cost-effectiveness was estimated using Quality Adjusted Life Years (QALYs) and life years gained as primary outcome measures. The cost per QALY gained of treating postmenopausal women without prior vertebral fractures was £18,000, £23,000, £18,000 and £21,000 at 50, 60, 70 and 80 years of age. Corresponding estimates for women with prior vertebral fractures were £10,000, £24,000, £18,000 and £20,000. In relation to threshold values that are recommended in the UK, the analysis suggests that raloxifene is cost-effective in the treatment of postmenopausal women at an increased risk of vertebral fractures.

Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637–645CrossRefPubMed

Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281:2189–2197CrossRefPubMed

Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, Rautaharju P, Harper KD (2002) Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 287:847–857CrossRefPubMed

Raftery J (2001) NICE: faster access to modern treatments? Analysis of guidance on health technologies. BMJ 323:1300–1303CrossRefPubMed

Johannesson M, Hedbrant J and Jonsson B (1991) A computer simulation model for cost-effectiveness analysis of cardiovascular disease prevention. Med Inform (Lond) 16:355–362

Zethraeus N, Johannesson M, Jonsson B (1999) A computer model to analyze the cost-effectiveness of hormone replacement therapy. Int J Technol Assess Health Care 15:352–365PubMed

Kanis JA, Dawson A, Oden A, Johnell O, de Laet C, Jonsson B (2001) Cost-effectiveness of preventing hip fracture in the general female population. Osteoporos Int 12:356–361CrossRefPubMed

Kanis JA, Johnell O, Oden A, De Laet C, Jonsson B, Dawson A (2002) Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategies. Bone 30:251–258CrossRefPubMed

Kanis JA, Johnell O, Oden A, De Laet C, Oglesby A, Jonsson B (2002) Intervention thresholds for osteoporosis. Bone 31:26–31CrossRefPubMed

10.

Kanis JA, Johnell O, Oden A, Jonsson B, Dawson A, Dere W (2000) Risk of hip fracture derived from relative risks: an analysis applied to the population of Sweden. Osteoporos Int 11:120–127PubMed

11.

Zethraeus N, Ben Sedrine W, Caulin F, Corcaud S, Gathon HJ, Haim M, Johnell O, Jonsson B, Kanis JA, Tsouderos Y, Reginster JY (2002) Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis. Osteoporos Int 13:841–857CrossRefPubMed

12.

Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, Ng KW, Stepan JJ, Powles TJ, Morrow M, Costa A, Silfen SL, Walls EL, Schmitt H, Muchmore DB, Jordan VC, Ste-Marie LG (2001) Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 65:125–134CrossRefPubMed

13.

Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C, Reginster JY, Pols HA, Recker RR, Harris ST, Wu W, Genant HK, Black DM, Eastell R (2002) Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87:3609–3617CrossRefPubMed

14.

Lothgren M, Zethraeus N (2000) Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Econ 9:623–630CrossRefPubMed

15.

Neele SJ, Evertz R, De Valk-De Roo G, Roos JC, Netelenbos JC (2002) Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women. Bone 30:599–603CrossRefPubMed

16.

Michaelsson K, Baron JA, Farahmand BY, Johnell O, Magnusson C, Persson PG, Persson I, Ljunghall S (1998) Hormone replacement therapy and risk of hip fracture: population based case-control study. The Swedish Hip Fracture Study Group. BMJ 316:1858–1863PubMed

17.

Felson DT, Zhang Y, Hannan MT, Kiel DP, Wilson PW, Anderson JJ (1993) The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 329:1141–1146CrossRefPubMed

18.

Stevenson JC, Kanis JA, Christiansen C (1992) Bone-density measurement. Lancet 339:370–371CrossRef

19.

Million Women Study Collaborators (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419–427CrossRefPubMed

20.

Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A, De Laet C, Jonsson B (2000) Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int 11:669–674CrossRefPubMed

21.

Felsenberg D, Silman A, Lunt M, Ambrecht G, Ismail A (2002) Incidence of Vertebral Fracture in Europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res 17:716–724PubMed

22.

Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254–1259PubMed

23.

Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721–739PubMed

24.

Cancer Statistics Registrations—Registrations of cancer diagnosed in 1998, England. Office for National Statistics: London, 2002

25.

Cauley JA, Lucas FL, Kuller LH, Vogt MT, Browner WS, Cummings SR (1996) Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group. JAMA 276:1404–1408CrossRefPubMed

26.

Zhang Y, Kiel DP, Kreger BE, Cupples LA, Ellison RC, Dorgan JF, Schatzkin A, Levy D, Felson DT (1997) Bone mass and the risk of breast cancer among postmenopausal women. N Engl J Med 336:611–617CrossRefPubMed

27.

Kannel W, Wolf P, Garrison R (1987) The Framingham study: an epidemiological investigation of cardiovascular disease. US Department of Commerce National Technical Information Service, Springfield

28.

Silverstein MD, Heit JA, Mohr DN, Petterson TM, O’Fallon WM and Melton LJ 3rd (1998) Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Int Med 158:585–593CrossRef

29.

Technology Appraisals Series No. 5: Guidance for Manufacturers and Sponsors (2001) National Institute for Clinical Excellence

30.

Dolan P, Torgerson DJ (1998) The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporos Int 8:611–617CrossRefPubMed

31.

Kanis J, Brazier J, Stevenson M, Calvert W, Jones ML (2002) Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technology Assessment 6:1–146

32.

De Laet CE, van Hout BA, Burger H, Weel AE, Hofman A, Pols HA (1999) Incremental cost of medical care after hip fracture and first vertebral fracture: the Rotterdam study. Osteoporos Int 10:66–72CrossRefPubMed

33.

Hutton J, Brown R, Borowitz M, Abrams K, Rothman M, Shakespeare A (1996) A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer. Pharmacoeconomics 9 Suppl 2:8–22

34.

Sanderson C, Kubin M (2001) Prevention of coronary heart disease through treatment of infection with Chlamydia pneumoniae? Estimation of possible effectiveness and costs. Health Care Manag Sci 4:269–279CrossRefPubMed

35.

Daly E, Vessey MP, Barlow D, Gray A, McPherson K, Roche M (1996) Hormone replacement therapy in a risk-benefit perspective. Maturitas 23:247–259CrossRefPubMed

36.

Netten A, Rees T, Harrison G (2001) Unit costs of health and Social Care. Personal Social Services Research Unit, University of Kent. www.ukc.ac.uk/PSSRU/

37.

Zethraeus N, Borgström F, Johnell I, Kanis JA, Jönsson B (2002) Costs and quality of life associated with osteoporosis related fractures—results from a Swedish survey. Working Paper Series in Economics and Finance, 512

38.

Lundberg L (1999) Health-related quality of life in Sweden. Faculty of Pharmacy, Uppsala University

39.

Kanis J, Johnell O, Oden A, Borgström F, Zethraeus N, Laet CD, Jönsson B (2004) The risk and burden of vertebral fracture in Sweden. Osteoporosis Int 15:20–26CrossRef

40.

Kind P, Dolan P, Gudex C, Williams A (1998) Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 316:736–741PubMed

41.

Johnell O, Jonsson B, Jonsson L, Black D (2003) Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 21:305–314PubMed

42.

Iglesias CP, Torgerson DJ, Bearne A, Bose U (2002) The cost utility of bisphosphonate treatment in established osteoporosis. Q J Med 95:305–311CrossRef

43.

Johannesson M (1995) The cost effectiveness of hypertension treatment in Sweden. Pharmacoeconomics 7:242–250PubMed

44.

Interim Life Tables (2002) Government Actuary’s Department

45.

Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D (2000) Risk of mortality following clinical fractures. Osteoporos Int 11:556–561CrossRefPubMed

46.

Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353:878–882CrossRefPubMed

47.

Cooper C, Atkinson EJ, Jacobsen SJ, O’Fallon WM, Melton LJ 3rd (1993) Population-based study of survival after osteoporotic fractures. Am J Epidemiol 137:1001–1005PubMed

48.

Johnell O, Kanis JA, Odén A, Sernbo I, Redlund-Johnell I, Petterson C, Laet CD, Jönsson B (2004) Mortality after osteoporotic fractures. Osteoporos Int 15:38–42CrossRefPubMed

49.

Heit JA, Mohr DN, Silverstein MD, Petterson TM, O’Fallon WM, Melton LJ 3rd (2000) Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Int Med 160:761–768CrossRef

50.

Kearon C (2003) Natural history of venous thromboembolism. Circulation 107:122–130CrossRef

51.

Frost ML, Blake GM, Fogelman I (2001) Quantitative ultrasound and bone mineral density are equally strongly associated with risk factors for osteoporosis. J Bone Miner Res 16:406–416PubMed

52.

Kanis JA, Johnell O, Oden A, Jonsson B, De Laet C, Dawson A (2000) Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone 27:585–590CrossRefPubMed

53.

Kanis J, Johnell O, Black D, Downs R, Sarkar S, Feurst T, Secrest R, Pavo I (2003) Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women defined by total hip bone mineral density. Bone 33:293–300CrossRefPubMed

54.

Stock JL, Bell NH, Chesnut CH 3rd, Ensrud KE, Genant HK, Harris ST, McClung MR, Singer FR, Yood RA, Pryor-Tillotson S, Wei L, Santora AC 2nd (1997) Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am J Med 103:291–297CrossRefPubMed

55.

Tonino RP, Meunier PJ, Emkey R, Rodriguez-Portales JA, Menkes CJ, Wasnich RD, Bone HG, Santora AC, Wu M, Desai R, Ross PD (2000) Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 85:3109–3115CrossRefPubMed

56.

Bagger YZ, Tanko LB, Alexandersen P, Hansen HB, Mollgaard A, Ravn P, Qvist P, Kanis JA, Christiansen C (2004) Two to three years of hormone replacement treatment in healthy women have long-term prevention effects on bone mass and osteoporotic fractures: the PERF study. Bone 34:728–735CrossRefPubMed

57.

Jalava T, Sarna S, Pylkkanen L, Mawer B, Kanis JA, Selby P, Davies M, Adams J, Francis RM, Robinson J, McCloskey EV (2003) Association between vertebral fracture and increased mortality in osteoporotic patients. J Bone Miner Res 18:1254–1260PubMed

58.

National Osteoporosis Foundation (1998) Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effective analysis. Osteoporos Int 8 (Suppl 4):1–88CrossRef

59.

Brazier JE, Green C, Kanis JA (2002) A systematic review of health state utility values for osteoporosis-related conditions. Osteoporos Int 13:768–776CrossRefPubMed

60.

Inglesias CP, Torgerson DJ, Bearne A, Bose U (2002) The cost utility of bisphosphonate treatment in established osteoporosis. Q J Med 95:305–311CrossRef

61.

Kanis JA, Borgstrom F, Johnell O, Jonsson B (2004) Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporos Int (in press)

62.

Borgstrom F, Johnell O, Kanis JA, Oden A, Sykes D, Jonsson B (2004) Cost-effectiveness of raloxifene in Sweden. An economic evaluation based on the MORE study. Pharmacoeconomics (in press)

Title: Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study
Authors: J. A. Kanis
F. Borgström
O. Johnell
A. Oden
D. Sykes
B. Jönsson
Publication date: 01-01-2005
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 1/2005
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-004-1688-0

At a glance: The STEP trials

Springer Medicine

Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2005

Steroid effects on osteogenesis through mesenchymal cell gene expression

Significance of intima-media thickness in femoral artery in the determination of calcaneus osteo-sono index but not of lumbar spine bone mass in healthy Japanese people

Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden

Bone mineral density of the spine and femur in healthy Saudis

Low levels of 25-hydroxy vitamin D are associated with elevated parathyroid hormone in healthy adolescent females

Assessment of anthropometric, systemic, and lifestyle factors influencing bone status in the legs of spinal cord injured individuals